Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion ...

Christopher Gibson, Co-Founder and CEO, announced, "beginning January 1, the amazing Najat Khan is going to take over the role of CEO, President and Director of Recursion." Gibson will transition to ...